ArticleBMC women's health2022
Estradiol and intrauterine device treatment for moderate and severe intrauterine adhesions after transcervical resection.
Article in BMC women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Effect of magnetic thermal vibration therapy combined with Femoston on endometrial repair in postoperative patients with moderate to severe intrauterine adhesions: a randomized controlled trial.Frontiers in endocrinology · 2026Trial
- Unraveling the fibrotic microenvironment in intrauterine adhesions through integrated metabolomics and proteomics.BMC women's health · 2026Article
- Co-delivery of endometrial mesenchymal stem cells and macrophages with an electrospun patch suppresses endometrial fibrosis via IL-10 related signaling.Frontiers in immunology · 2026Article
- Prognostic Factors and Predictive Models for Reproductive Outcomes in Patients with Intrauterine Adhesions: A Review.International journal of women's health · 2026Review
- Retrospective study on constructing a nomogram model based on clinical data to predict the recurrence probability of patients with intrauterine adhesions after separation surgery.Frontiers in medicine · 2026Article
- Functionalized bacterial cellulose membranes with controlled biodegradation and β-estradiol delivery properties for potential intrauterine adhesion prevention.Journal of materials science. Materials in medicine · 2025Article
- Article
- From Adhesions to Conception: A Case Study on Platelet-Rich Plasma's Role in Gynecologic Recovery.Cureus · 2025Article
- Review of Asherman syndrome and its hysteroscopic treatment outcomes: experience in a low-resource setting.BMC women's health · 2024Review
- Comparison of Secondary Prevention Following Hysteroscopic Adhesiolysis in the Improvement of Reproductive Outcomes: A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Decoding the endometrial niche of Asherman's Syndrome at single-cell resolution.Nature communications · 2023Article
- Article
- Treatment of septate uterus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effect of 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) in patients with moderate and severe intrauterine adhesion (IUA) after transcervical resection of adhesion (TCRA).
methodsPatients with moderate or severe IUA who reived 4 mg/day, 6 mg/day, and 8 mg/day estradiol alone or in combination with an intrauterine device (IUD) after TCRA in Women's Hospital, Zhejiang University School of Medicine, from March 2014 to December 2014 were enrolled in this retrospective case-control study. In group A, 14 patients received estradiol 4 mg/day + IUD after the first operation; in group B, 29 patients (group B0) received estradiol 6 mg/day after the first operation, and 73 patients (group B1) received estradiol 6 mg/day + IUD; in group C, 14 patients received estradiol 8 mg/day + IUD after the first operation. Referring to ESGE's IUA diagnostic classification method, 72 patients had moderate adhesion, and 58 cases had severe adhesion. Outpatient follow-up was performed at 1 and 23 months and after 1 year. The postoperative menstrual improvement, uterine cavity recovery, drug side effects at two to three months, and pregnancy situation at one year were recorded.
resultsThere were no significant differences in age, BMI, and previous intrauterine operation times between the 3 groups (all p > 0.05). Compared with Group A, more patients in group C had severe IUA (p = 0.008). In addition, there were no differences in menstrual recovery, uterine cavity recovery, and pregnancy in one year between the 3 groups (p > 0.05) and between groups B
conclusionThis data suggests that 4 mg/d doses of estrogen may have the same effect in improving the menstrual condition, uterine cavity morphology, and reproductive ability compared to a higher dosage (6 mg/day estrogen and 8 mg/day). In addition, the placement of IUD in the uterine cavity during TCRA may cause IUD incarceration, and the treatment results for the prevention of IUA are not better than without IUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.